Sarepta Therapeutics Shares Crash 40% After Key Drug Trial Fails to Show Benefits

Sarepta Therapeutics stock plunges as confirmatory trial for DMD drugs misses primary endpoint, adding to company's recent setbacks including Elevidys safety concerns.